Pancrelipase Improves Stool Frequency and Consistency in EPI
Participants had a 5-day placebo run-in period and then were randomly assigned to pancrelipase (72,000 LU/meal; 36,000 LU/snack) or placebo for a 7-day, double-blind period.
Diagnosis & Disease Information
MPR Weekly Dose Podcast #130
This week, news of the FDA’s vote on AMX0035, the novel ALS treatment; CPAP and BiPAP device recalls; Orphan Drug designation for a novel CRISPR therapy; Imfinzi gains new approval; and Spevigo is approved for pustular psoriasis flares.
Sucraid Single-Use Containers Approved for Congenital Sucrase-Isomaltase Deficiency
Sucraid is an oral enzyme replacement therapy of the genetically determined sucrase deficiency.
Imfinzi Plus Chemotherapy Approved for Advanced Biliary Tract Cancer
The approval was based on data from the phase 3 TOPAZ-1 trial.
May 2022: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
Durvalumab Plus Chemo Granted Priority Review for Biliary Tract Cancer
The sBLA was supported by data from the phase 3 TOPAZ-1 trial.
Guidelines Updated for Barrett Esophagus Diagnosis, Management
Guideline revised to synthesize current best practices in the management of Barrett esophagus
GLP-1 RA Use May Up Risk for Gallbladder, Biliary Diseases
GLP-1 RA treatment linked to increased risk, especially in trials for weight loss, and with higher doses and longer duration of use
Adding Immunotherapy to Chemo Ups Survival in Advanced Biliary Tract Cancer
Overall survival, progression-free survival prolonged in those receiving durvalumab versus placebo in addition to gemcitabine and cisplatin
